Meet CBP

Meet CBP

About CBP

Established in 2016, Coherent Biopharma is a clinical-stage biopharmaceutical company focused on R&D and commercialization of bi-targeting XDC drugs. The management team of the Company consists of experts in biotechnology R&D, medicinal chemistry/CMC, clinical study, and business development with global industrial experience.

Read more

15

Proprietary Technology

1 Proprietary Platform Technology
5+ First-in-Class Assets
15+ Global IP Protection

110

Professional Staff

5+ Top scientists & industry experts
110+ Expert professionals.

25

Solid Portfolio

5 Potential First-in-Class
10+ Products
10+ Oncology Indication Clinical Trials

3

Global Operation

Integrated management organization in China, the U.S and Australia

Our Culture

Vision

Build a world-class bioecology company and create a global coherent biopharma brand

Values

Sincere attitude towards collaboration;
Erudition and insightful thinking;
Innovation to drive progress;
Pragmatic and win-win cooperation

Mission

Cancer treatment and beyond； Leading pharmaceutical innovation； Advancing towards a healthy life

Executive Committee

Our History

Coherent Biopharma - the Bi-XDC company

  • Established in 2016, Coherent Biopharma is a clinical-stage biopharmaceutical company focused on R&D and the commercialization of bi-targeting XDC drugs. The management team of the Company consists of experts in biotechnology R&D, medicinal chemistry/CMC, clinical study, and business development with global industrial experience.
  • Coherent Biopharma’s proprietary bi-targeting XDC technology is pioneering a new pathway for drug development. With the ability to actively and cell/tissue-specifically deliver any bioactive molecule, bi-targeting XDC technology of CBP has the potential to overcome the undruggability obstacle of a variety of molecules with high bioactivity, thus enabling the targeting of previously undruggable.
  • The company currently has three oncology products and seven clinical trials underway in China and the United States. For its leading asset CBP-1008 moving into pivotal trails, a total of 350 patients has been treated demonstrating impressive efficacy and safety profile for Ovarian cancer patient with low to high Folate Receptor alpha including Ovarian Clear Cell Carcinoma. CBP-1018, targeting PSMA receptor has also demonstrated a superior profile in Phase I/II studies with over 150 Prostate cancer patients treated, showing >7 months of mPFS for 3rd line mCRPC patients. Finally, for its next-gen drug, CBP-1019, a multi-regional Phase I/II has shown incredible safety and efficacy advantages compared to ADCs with TOPI inhibitors. In addition, multiple candidates are in IND-enabling or early stage including bi-XDC with PROTACs and Radio Pharm Therapy (RPT).